Bita Fakhri, MD, MPH

Articles

Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL

August 13th 2024

The panel concludes its discussion with a look to the future of CLL treatment, focusing on emerging novel agents and exciting clinical research.

Updates in CLL Treatment Strategies with Noncovalent BTKis

August 6th 2024

Highlighting recent clinical trial data on pirtobrutinib in patients with chronic lymphocytic leukemia, the panel shares their experience utilizing it in clinical practice.

Management Strategies for BTKi-Related CVAEs in CLL

August 6th 2024

Bita Fakhri, MD, MPH, shares her general approach to managing common cardiovascular adverse events associated with BTK inhibitors in patients with chronic lymphocytic leukemia.

Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications

July 30th 2024

The panel addresses the intricacies of treating patients with chronic lymphocytic leukemia who experience treatment resistance.

Navigating 2L Treatment Options in CLL

July 30th 2024

Experts on chronic lymphocytic leukemia discuss treatment practices for patients with relapsed/refractory CLL and provide insights on the role for venetoclax in patients who previously received BTK inhibitors.

Patient with R/R CLL Treated with 2L Venetoclax Therapy

July 23rd 2024

A hematology and oncology specialist presents the case of a 66-year-old man with chronic lymphocytic leukemia.

Expert Insights for Long-Term Treatment Planning in CLL

July 23rd 2024

Catherine C. Coombs, MD, outlines considerations for long-term treatment planning, particularly in younger patients with chronic lymphocytic leukemia.

Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL

July 16th 2024

John N. Allan, MD, provides clinical insights on how appropriate dose ramp-up practices for venetoclax can minimize adverse events and optimize patient outcomes.

Perspectives on Shared Decision-Making in the Treatment of CLL

July 16th 2024

Bita Fakhri, MD, MPH, discusses the importance of patient involvement in the shared decision-making process to individualize treatment and improve outcomes.

Considerations for 1L Doublet and Triplet Therapy with Venetoclax in CLL

July 9th 2024

Experts on chronic lymphocytic leukemia detail how clinical trial data on doublet therapies help inform treatment decisions in the first line.

Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL

July 9th 2024

Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies and factors that inform treatment selection.

Implications of Real-World Data in the 1L Treatment of High-Risk CLL

July 3rd 2024

Catherine C. Coombs, MD, discusses the value of real-world data in informing the treatment of patients with chronic lymphocytic leukemia.

Navigating Continuous BTKi Therapy for CLL in the 1L Setting

July 3rd 2024

John N. Allan, MD, describes how he selects patients for first-line treatment with continuous BTK inhibitor therapy, referencing data from the RESONATE-2, ELEVATE-TN, and SEQUOIA studies.

Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL

June 25th 2024

Bita Fakhri, MD, MPH, outlines factors she considers when choosing between fixed-duration and continuous BTK inhibitor therapy and discusses how she approaches treatment discussions with patients.

Patient with Newly Diagnosed CLL with High-Risk Features

June 25th 2024

A panel of experts on chronic lymphocytic leukemia (CLL) review a patient case and describe their initial impressions on treatment decisions.

Dr. Fakhri on Ongoing Clinical Trials in CLL

February 18th 2020

Bita Fakhri, MD, MPH, assistant professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses ongoing clinical trials in chronic lymphocytic leukemia (CLL).

Dr. Fakhri on the Use of PI3K Inhibitors in Relapsed/Refractory CLL

January 24th 2020

Bita Fakhri, MD, MPH, assistant professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of PI3K inhibitors in relapsed/refractory chronic lymphocytic leukemia (CLL).

Dr. Fakhri on Tumor Lysis Syndrome Associated With Venetoclax/Obinutuzumab in CLL

January 16th 2020

Bita Fakhri, MD, MPH, discusses concern over the tumor lysis syndrome that occurred in the CLL14 trial that looked at patients with previously untreated chronic lymphocytic leukemia.

Dr. Fakhri on Selecting the Optimal Treatment in CLL

January 10th 2020

Bita Fakhri, MD, MPH, discusses considerations in selecting the optimal treatment in chronic lymphocytic leukemia.

Dr. Fakhri on Ibrutinib-Containing Regimens in CLL

December 21st 2019

Bita Fakhri, MD, MPH, discusses the trials that led to ibrutinib-containing regimens becoming the standard of care for chronic lymphocytic leukemia over traditional chemotherapy options.